Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs OneSpan Inc (OSPN) Price & Performance

Halozyme Therapeutics Inc. Common StockTrade
OneSpan IncTrade

Price performance (Past 24H)

Key statistics

Halozyme Therapeutics Inc. Common Stock vs OneSpan Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.28 (market cap $12.58B), while OneSpan Inc trades at $18.14 (market cap $662.97M). The key difference: Halozyme Therapeutics Inc. Common Stock is far larger — about 19× OneSpan Inc's market cap, and OneSpan Inc pays a 2.89% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and OneSpan Inc for 18 Days on average.

HALOOSPN
Market Cap
$12.58B$662.97M
Volume
2,179,278616,882
Sector
HealthTechnology
52-Week High
$115.22$18.42
52-Week Low
$61.63$10.15
Typical Hold Time
1 Days18 Days
Enterprise Value
$14.49B$632.05M
Dividend Yield
—2.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Halozyme Therapeutics Inc. Common Stock

No Aura AI signal available yet.

OneSpan Inc

OneSpan (OSPN) trades at $17.70, down 3.7% in the last session, but maintains strong fundamentals with consistent earnings beats and robust profitability. The stock shows a bullish technical signal with support at $17 and resistance at $18. Recent Q2 2026 results exceeded expectations with EPS of $0.30 versus $0.231 expected, while the company introduced new authentication technology to drive future growth.

The outlook remains positive given strong analyst support (66.7% buy ratings) and solid financial metrics, though investors should monitor declining cash flow trends and competitive pressures in the cybersecurity sector. The stock presents value opportunity with P/E of 10.16 and ROE of 26.51%, but faces execution risks in maintaining subscription revenue growth.

Returns comparison

Trailing returns across standard periods

About Halozyme Therapeutics Inc. Common Stock

Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.

Read more on HALO →

About OneSpan Inc

OneSpan Inc. is a global leader in providing digital agreement security solutions. The company's platform helps organizations, primarily in the financial services sector, to secure their digital agreements and transactions, including e-signatures, multi-factor authentication, and transaction monitoring. OneSpan's technology is focused on protecting customers from fraud and meeting regulatory compliance requirements in a digital-first environment.

Read more on OSPN →